- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00141024
Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Protein Vaccine EP-1043 and the DNA Vaccine EP HIV-1090 Given Alone or in Combination in Healthy, HIV-1-Uninfected Adult Participants
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The worldwide HIV/AIDS epidemic may only be controlled through the development of a safe and effective vaccine that will prevent HIV infection. DNA vaccines are inexpensive to construct, readily produced in large quantities, and stable for long periods of time. EP HIV-1090 is a DNA HIV CTL vaccine; the proteins for which its genes code are designed to interact with CD8 cells (CTL) and cause CD8 cell proliferation. The DNA plasmids in EP HIV-1090 code for proteins conserved among HIV subtypes A, B, C, D, F, and G, which encompass the HLA subtypes of 85% of the worldwide general population.
Participants will be enrolled in this study for 1 year. Group 4 participants will receive EP HIV-1090 or placebo at study entry and Months 1, 3, and 6. There will be 11 study visits that will occur at screening; study entry; and Months 0.5, 1, 1.5, 3, 3.5, 6, 6.5, 9, and 12. A physical exam and risk reduction/pregnancy prevention counseling will occur at each visit. Participants will be asked about their adverse experiences from vaccination at each visit. Blood and urine collection will occur at selected visits.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94102-6033
- San Francisco Vaccine and Prevention CRS
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- Project Brave HIV Vaccine CRS
-
-
New York
-
Rochester, New York, United States, 14642-0001
- Univ. of Rochester HVTN CRS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Note: Groups 1, 2, 3, and 5 have permanently discontinued enrollment per the 12/26/06 letter of amendment.
Inclusion Criteria:
- Good general health
- Have access to a participating HIV Vaccine Trials Unit (HVTU) and are willing to be followed for the duration of the study
- Willing to receive HIV test results
- Have understanding of the study
- Willing to use acceptable forms of contraception
- Negative pregnancy test
Exclusion Criteria:
- HIV vaccines in a prior HIV vaccine trial
- Immunosuppressive medications within 168 days prior to first vaccination
- Blood products within 120 days prior to first vaccination
- Immunoglobulin within 60 days prior to first vaccination
- Live attenuated vaccines within 30 days prior to first vaccination
- Investigational research agents within 30 days prior to first vaccination
- Medically indicated subunit or killed vaccines within 14 days prior to first study vaccine administration, or allergy treatment with antigen injections within 30 days prior to first vaccination
- Current tuberculosis prophylaxis or therapy
- Clinically significant medical condition, abnormal physical exam findings, abnormal laboratory results, or past medical history that may affect current health
- Any medical, psychiatric, or social condition that would interfere with the study. More information about this criterion can be found in the protocol.
- Any job-related responsibility that would interfere with the study
- Serious adverse reaction to vaccines. A person who had an adverse reaction to pertussis vaccine as a child is not excluded.
- Autoimmune disease or immunodeficiency
- Active syphilis infection unless the participant has completed full treatment for syphilis 6 months prior to enrollment
- Unstable asthma
- Diabetes mellitus type 1 or 2
- Thyroid disease or thyroidectomy requiring treatment
- Serious angioedema within 3 years prior to enrollment
- Uncontrolled hypertension
- Body mass index (BMI) of 40 or greater
- BMI of 35 or greater if the participant is older than 45 years, has systolic blood pressure greater than 140 mm Hg, has diastolic blood pressure greater than 90 mm Hg, smokes, or has known hyperlipidemia
- Bleeding disorder
- Malignancy unless it has been surgically removed and, in the opinion of the investigator, is not likely to recur during the study period
- Seizure disorder requiring medication within the 3 years prior to enrollment
- Absence of the spleen
- Mental illness that would interfere with the study
- Other conditions that, in the judgment of the investigator, would interfere with the study
- Pregnancy, breastfeeding, or plans to become pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Group 1 will receive 4 vaccinations of the EP-1043 vaccine or placebo.
Vaccinations will be given at Months 0, 1, 3, and 6.
This group was discontinued as of 12/26/06.
|
Recombinant protein vaccine containing the 18 HIV proteins from HIV genes Pol, Vpu, and Gag. The vaccine is provided in single-use 1.1-mL vials. |
Experimental: 2
Group 2 will receive 4 vaccinations of the EP-1043 vaccine or placebo.
Vaccinations will be given at Months 0, 1, 3, and 6.
This group was discontinued as of 12/26/06.
|
Recombinant protein vaccine containing the 18 HIV proteins from HIV genes Pol, Vpu, and Gag. The vaccine is provided in single-use 1.1-mL vials. |
Experimental: 3
In Part B, Group 3 will receive 4 vaccinations of either the EP-1043 vaccine or placebo.
Vaccinations will occur at Months 0, 1, 3, and 6.
This group was discontinued as of 12/26/06.
|
Recombinant protein vaccine containing the 18 HIV proteins from HIV genes Pol, Vpu, and Gag. The vaccine is provided in single-use 1.1-mL vials. |
Experimental: 4
In Part B, Group 4 will receive 4 vaccinations of either the DNA vaccine EP-HIV-1090 or placebo.
Vaccinations will occur at Months 0, 1, 3, and 6.
|
DNA plasmid vaccine containing the genes Gag, Pol, Vpr, Nef, Rev, and Env.
The vaccine is provided in single-use 1.1-mL vials.
|
Experimental: 5
In Part B, Group 5 will receive 4 vaccinations of either the protein vaccine EP-1043 plus DNA vaccine EP-HIV- 1090 or placebo.
Vaccinations will occur at Months 0, 1, 3, and 6.
This group was discontinued as of 12/26/06.
|
Recombinant protein vaccine containing the 18 HIV proteins from HIV genes Pol, Vpu, and Gag. The vaccine is provided in single-use 1.1-mL vials.
DNA plasmid vaccine containing the genes Gag, Pol, Vpr, Nef, Rev, and Env.
The vaccine is provided in single-use 1.1-mL vials.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety as assessed by local and systemic reactogenicity signs and symptoms, laboratory measures, and adverse and serious experiences
Time Frame: After each injection and for 12 months following the first injection
|
After each injection and for 12 months following the first injection
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Immunogenicity as assessed by HIV-specific cellular responses assessed by interferon-gamma ELISpot assays and intracellular cytokine staining
Time Frame: Throughout the study
|
Throughout the study
|
Social impacts as assessed by negative experiences or problems reported by the participants
Time Frame: Throughout the study
|
Throughout the study
|
Collaborators and Investigators
Investigators
- Study Chair: Xia Jin, MD, PhD, University of Rochester
- Study Chair: Jorge Sanchez, MD, Asociación Civil Impacta Salud y Educación (IMPACTA)
Publications and helpful links
General Publications
- Jin X, Morgan C, Yu X, DeRosa S, Tomaras GD, Montefiori DC, Kublin J, Corey L, Keefer MC; NIAID HIV Vaccine Trials Network. Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials. Vaccine. 2015 May 11;33(20):2347-53. doi: 10.1016/j.vaccine.2015.03.036. Epub 2015 Mar 25.
- Wilson CC, McKinney D, Anders M, MaWhinney S, Forster J, Crimi C, Southwood S, Sette A, Chesnut R, Newman MJ, Livingston BD. Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1. J Immunol. 2003 Nov 15;171(10):5611-23. doi: 10.4049/jimmunol.171.10.5611.
- Esparza J, Osmanov S. HIV vaccines: a global perspective. Curr Mol Med. 2003 May;3(3):183-93. doi: 10.2174/1566524033479825.
- Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V, Haynes B, Hahn BH, Bhattacharya T, Korber B. Diversity considerations in HIV-1 vaccine selection. Science. 2002 Jun 28;296(5577):2354-60. doi: 10.1126/science.1070441.
- Livingston BD, Newman M, Crimi C, McKinney D, Chesnut R, Sette A. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine. 2001 Sep 14;19(32):4652-60. doi: 10.1016/s0264-410x(01)00233-x.
- McKinney DM, Skvoretz R, Livingston BD, Wilson CC, Anders M, Chesnut RW, Sette A, Essex M, Novitsky V, Newman MJ. Recognition of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL. J Immunol. 2004 Aug 1;173(3):1941-50. doi: 10.4049/jimmunol.173.3.1941.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HVTN 064
- 10059 (Registry Identifier: DAIDS ES Registry Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on EP HIV-1043
-
National Institute of Allergy and Infectious Diseases...CompletedHIV InfectionsBotswana, United States
-
National Institute of Allergy and Infectious Diseases...CompletedHIV InfectionsUnited States
-
eXIthera PharmaceuticalsWithdrawnCovid19 | ThrombopeniaUnited States
-
Sunovion Respiratory Development Inc.Completed
-
BioSig Technologies, Inc.Completed
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
BioSig Technologies, Inc.Completed
-
Boston Scientific CorporationCompleted
-
Kansas City Heart Rhythm Research FoundationNot yet recruitingCardiac ArrhythmiasUnited States
-
Ulrich MehnertRecruitingLower Urinary Tract SymptomsSwitzerland